filmov
tv
Dr. McGregor on Immunotherapy in Rare Genitourinary Cancers
Показать описание
Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses immunotherapy in rare genitourinary (GU) cancers.
0:01:49
Dr. McGregor on New Combinations With Immunotherapy in RCC
0:01:54
Dr. McGregor on Immunotherapy in Rare Genitourinary Cancers
0:01:49
Dr. McGregor on Immunotherapy Combinations in Kidney Cancer
0:00:56
Dr McGregor on the Future Implications of Ongoing Research in RCC
0:01:18
Dr McGregor on the Rationale for the DAD Trial in Metastatic Urothelial Cancer
0:01:22
Copy of Dr. McGregor on Implications of the FDA Approval of Pembrolizumab/Axitinib in RCC
0:01:12
Dr. McGregor on Frontline Regimens in Advanced RCC
0:01:23
Dr. McGregor on Unmet Needs in Advanced RCC
0:01:16
Dr. McGregor on Combination Therapies With Nivolumab, Cabozantinib, and Sunitinib in RCC
0:02:02
Dr. McGregor on Implications of the FDA Approval of Pembrolizumab/Axitinib in RCC
0:01:14
Dr. McGregor on the Combination of Atezolizumab and Bevacizumab in RCC
0:01:47
Dr. McGregor on Choosing a Combination Therapy Regimen in Advanced RCC
0:02:20
Dr. McGregor on Advances Made in the Adjuvant Setting of RCC
0:01:26
Dr McGregor on the Updated NCCN Guidelines for Non–Clear Cell RCC
0:02:06
Dr. McGregor on Whether Patients Need Frontline Combinations in RCC
0:01:16
Dr. McGregor Discusses the Future of Treatment for RCC
0:01:02
Current status of VEGF inhibitor/immunotherapy combinations in RCC
0:01:32
Dr. McGregor on the Future of Cabozantinib in RCC
0:03:30
Summary of Immunotherapy CME Presentation: Xin Gao, MD
0:01:03
Dr. McGregor on the Evolving Treatment Landscape of RCC
0:01:34
Dr McGregor on the Clinical Implications of the DAD-IO Trial in Urothelial Carcinoma
0:01:08
Dr. McGregor on Unmet Needs in Non-Clear Cell RCC
0:05:55
The Best Diet for Cancer Patients
0:10:28
Responses to Traditional Chemotherapy Vs Immunotherapy
Комментарии